Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2020

June 2020 | 134 pages | ID: ME3050FFC5AEN
Global Markets Direct

Abstracts

Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome - Pipeline Review, H1 2020, provides an overview of the Middle East Respiratory Syndrome (Infectious Disease) pipeline landscape.
Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Middle East Respiratory Syndrome (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 17, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 7 molecules, respectively.
Middle East Respiratory Syndrome (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Middle East Respiratory Syndrome (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Middle East Respiratory Syndrome (MERS) - Overview
Middle East Respiratory Syndrome (MERS) - Therapeutics Development
Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
Middle East Respiratory Syndrome (MERS) - Drug Profiles
Middle East Respiratory Syndrome (MERS) - Dormant Projects
Middle East Respiratory Syndrome (MERS) - Discontinued Products
Middle East Respiratory Syndrome (MERS) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by AIM ImmunoTech Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Anglo Biopharma Ltd, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Atriva Therapeutics GmbH, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Autoimmune Technologies LLC, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Celltrion Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Cocrystal Pharma Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Future Medicine Co Ltd, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Gilead Sciences Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Global BioLife Inc Ltd, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Greffex Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Humabs BioMed SA, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Inovio Pharmaceuticals Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by LegoChem Biosciences Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by NanoViricides Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Novavax Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Orgenesis Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Ostrich Pharma USA Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by OyaGen Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Phelix Therapeutics LLC, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Pulmotect Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Ridgeback Biotherapeutics LP, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Romark Laboratories LC, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by SAB Biotherapeutics Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Signia Therapeutics, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by AIkido Pharma Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Sumagen Co Ltd, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Themis Bioscience GmbH, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Theravectys SA, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by Vaccitech Ltd, H1 2020
Middle East Respiratory Syndrome (MERS) - Pipeline by VBI Vaccines Inc, H1 2020
Middle East Respiratory Syndrome (MERS) - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AIM ImmunoTech Inc
Anglo Biopharma Ltd
Atriva Therapeutics GmbH
Autoimmune Technologies LLC
Celltrion Inc
Chongqing Zhifei Biological Products Co Ltd
Cocrystal Pharma Inc
Future Medicine Co Ltd
Gilead Sciences Inc
Global BioLife Inc Ltd
Greffex Inc
Humabs BioMed SA
Inovio Pharmaceuticals Inc
LegoChem Biosciences Inc
NanoViricides Inc
Novavax Inc
Orgenesis Inc
Ostrich Pharma USA Inc
OyaGen Inc
Phelix Therapeutics LLC
Pulmotect Inc
Regeneron Pharmaceuticals Inc
Ridgeback Biotherapeutics LP
Romark Laboratories LC
SAB Biotherapeutics Inc
Signia Therapeutics
AIkido Pharma Inc
Sumagen Co Ltd
Themis Bioscience GmbH
Theravectys SA
Vaccitech Ltd
VBI Vaccines Inc